

documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205-2000. General information concerning the Commission may also be obtained by accessing its Internet server at <http://www.usitc.gov>. The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at <http://edis.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810.

**SUPPLEMENTARY INFORMATION:** The Commission instituted this investigation on June 21, 2011, based on a complaint filed by MOSAID Technologies Inc. of Ottawa, Canada ("MOSAID"), alleging violations of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain equipment for communications networks, including switches, routers, gateways, bridges, wireless access points, cable modems, IP phones and products containing same by reason of infringement of certain claims of U.S. Patent Nos. 7,035,280; 7,292,600; 7,830,858; 6,842,459; 7,633,966; and 5,841,360. 76 FR 36154-55 (June 21, 2011). The Notice of Investigation named the following as respondents: Cisco Systems, Inc. of San Jose, California; Cisco Consumer Products LLC of Irvine, California; Cisco Systems International B.V. of Amsterdam, Netherlands; and Scientific Atlanta LLC of Lawrenceville, California (collectively "Respondents"). The Office of Unfair Import Investigations was named as a party.

On March 14, 2012, MOSAID and Respondents jointly filed to terminate the investigation in its entirety based on a settlement agreement, which was attached to the motion. On March 21, 2012, the parties supplemented their motion to identify additional agreements that concern the investigation.

On March 21, 2012, the ALJ issued the subject ID granting the joint motion to terminate the investigation in its entirety pursuant to section 210.21(b) of the Commission's Rules of Practice and Procedure (19 CFR 210. 21(b)). No petitions for review of the subject ID were filed.

The Commission has determined not to review the ID.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in section 210.42 of the Commission's Rules of Practice and Procedure (19 CFR 210.42).

By order of the Commission.  
Issued: April 9, 2012.

**James R. Holbein,**

*Secretary to the Commission.*

[FR Doc. 2012-8851 Filed 4-11-12; 8:45 am]

**BILLING CODE 7020-02-P**

## DEPARTMENT OF JUSTICE

[OMB Number 1105-NEW]

### Agency Information Collection Activities: Proposed Collection; Comments Requested: September 11th Victim Compensation Fund Objection Form

**ACTION:** 30-Day Notice of Information Collection Under Review.

The Department of Justice (DOJ), Civil Division, September 11th Victim Compensation Fund, will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. This proposed information collection was previously published in the **Federal Register**, Volume 77, Number 20, Page 4827 on January 31, 2012, allowing for a 60 day comment period.

The purpose of this notice is to allow for an additional 30 days for public comment until May 14, 2012. This process is conducted in accordance with 5 CFR 1320.10.

Written comments concerning this information collection should be sent to the Office of Information and Regulatory Affairs, Office of Management and Budget, Attn: DOJ Desk Officer. The best way to ensure your comments are received is to email them to [oir\\_submission@omb.eop.gov](mailto:oir_submission@omb.eop.gov) or fax them to 202-395-7285. All comments should reference the 8 digit OMB number for the collection or the title of the collection. If you have questions concerning the collection, please call Jonathan Olin, 202-514-5585.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your

comments should address one or more of the following four points:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- Enhance the quality, utility, and clarity of the information to be collected; and
- Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

### Overview of This Information Collection

(1) *Type of Information Collection:* New collection.

(2) *Title of the Form/Collection:* Victim Compensation Objection Form.

(3) *Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection:* Form Number: N/A. Civil Division.

(4) *Affected public who will be asked or required to respond, as well as a brief abstract:* Primary: Anyone expressing a potential objection to the filing of a claim by a purported personal representative of a deceased victim. Abstract: This form is to be submitted in connection with potential objections made to claims filed with the September 11th Victim Compensation Fund of 2001. The form asks that the objection be characterized and explained or be withdrawn.

(5) *An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond:* 50 objectors with an average of 2.0 hours per response.

(6) *An estimate of the total public burden (in hours) associated with the collection:* There are an estimated 100 annual total burden hours associated with this collection.

If additional information is required contact: Jerri Murray, Department Clearance Officer, Policy and Planning Staff, Justice Management Division, Department of Justice, Two Constitution

Square, 145 N Street NE., Room 2E-508, Washington, DC 20530.

**Jerri Murray,**

*Department Clearance Officer, PRA, U.S. Department of Justice.*

[FR Doc. 2012-8398 Filed 4-11-12; 8:45 am]

**BILLING CODE 4410-12-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances: Notice of Application**

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on December 7, 2011, Meda Pharmaceuticals Inc., 705 Eldorado Street, Decatur, Illinois 62523, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Nabilone (7379), a basic class of controlled substance listed in schedule II.

The company plans to import the listed controlled substance for distribution to its customers.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration, and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than May 14, 2012.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, 40 FR 43745-46, all applicants for registration to import a basic class of any controlled substance listed in schedule I or II are, and will continue

to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: April 2, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2012-8761 Filed 4-11-12; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances, Notice of Application, Lipomed, Inc.**

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on January 30, 2012, Lipomed, Inc., One Broadway, Cambridge, Massachusetts 02142, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the following basic classes of controlled substances:

Drug	Schedule
Cathinone (1235) .....	I
Methcathinone (1237) .....	I
4-methyl-N-methylcathinone (1248) .....	I
N-Ethylamphetamine (1475) .....	I
N,N-Dimethylamphetamine (1480) .....	I
Fenethylamine (1503) .....	I
Aminorex (1585) .....	I
4-Methylaminorex (cis isomer) (1590) .....	I
Gamma Hydroxybutyric Acid (2010) .....	I
Methaqualone (2565) .....	I
Mecloqualone (2572) .....	I
1-Pentyl-3-(1-naphthoyl)indole (7118) .....	I
1-Butyl-3-(1-naphthoyl)-indole (7173) .....	I
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl) indole (7200) .....	I
Alpha-ethyltryptamine (7249) .....	I
Ibogaine (7260) .....	I
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-	I

Drug	Schedule
hydroxycyclohexyl]-phenol (7297) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-	I
hydroxycyclohexyl]-phenol (7298)	I
Lysergic acid diethylamide (7315)	I
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348) .....	I
Marihuana (7360) .....	I
Tetrahydrocannabinols (7370) .....	I
Parahexyl (7374) .....	I
Nabilone (7379) .....	I
Mescaline (7381) .....	I
3,4,5-Trimethoxyamphetamine (7390) .....	I
4-Bromo-2,5-dimethoxyamphetamine (7391) .....	I
4-Bromo-2,5-dimethoxyphenethylamine (7392) .....	I
4-Methyl-2,5-dimethoxyamphetamine (7395) .....	I
2,5-Dimethoxyamphetamine (7396) .....	I
2,5-Dimethoxy-4-ethylamphetamine (7399) .....	I
3,4-Methylenedioxyamphetamine (7400) .....	I
5-Methoxy-3,4-methylenedioxyamphetamine (7401) .....	I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402) .....	I
3,4-Methylenedioxy-N-ethylamphetamine (7404) .....	I
3,4-Methylenedioxymethamphetamine (7405) .....	I
4-Methoxyamphetamine (7411) .....	I
5-Methoxy-N,N-dimethyltryptamine (7431) .....	I
Alpha-methyltryptamine (7432) .....	I
Dimethyltryptamine (7435) .....	I
Psilocybin (7437) .....	I
Psilocyn (7438) .....	I
5-Methoxy-N,N-diisopropyltryptamine (7439) .....	I
N-Ethyl-1-phenylcyclohexylamine (7455) .....	I
1-(1-Phenylcyclohexyl)pyrrolidine (7458) .....	I
1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) .....	I
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine (7473) .....	I
N-Ethyl-3-piperidyl benzilate (7482) .....	I
N-Methyl-3-piperidyl benzilate (7484) .....	I
N-Benzylpiperazine (7493) .....	I
3,4-methylenedioxypropylvalerone (7535) .....	I
3,4-methylenedioxy-N-methylcathinone (7540) .....	I
Alphaprodine (9010) .....	I
Acetyldihydrocodeine (9051) .....	I
Benzylmorphine (9052) .....	I
Codeine-N-oxide (9053) .....	I
Cyprenorphine (9054) .....	I
Desomorphine (9055) .....	I
Etorphine (except HCl) (9056) .....	I